Atrial Fibrillation Trial, Recruiting NCT05664308 Sponsor: Nantes University Hospital Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Atrial Fibrillation Trial, Recruiting

NCT05664308
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults (18 years or older) who are scheduled to have open heart surgery using standard surgical methods.
  • People who develop a new irregular heartbeat (called atrial fibrillation) after their heart surgery, which was not present before the operation.
  • People who agree to take part in the study and sign a consent form.
  • People who agree to be monitored and followed up for 12 months after their surgery.

Who may not be able to join:

  • People who already had an irregular heartbeat (atrial fibrillation) before their surgery.
  • People who do not own a smartphone that works with the study's connected smartwatch.
  • People who are unable to take their own ECG (heart rhythm) reading using the watch independently.
  • People who have a physical condition on their arm or wrist that would prevent the watch from taking a reading, such as an arteriovenous fistula (a surgically created connection between an artery and vein, often used for dialysis).
  • Children and teenagers under 18 years of age.
  • Women who are pregnant or breastfeeding.
  • Adults who are under legal guardianship or a similar form of supervised legal protection.
  • People whose life expectancy is less than one year.
  • People who are already taking part in another clinical trial that could affect the results of this study.
  • People who have a medical reason why they cannot take blood-thinning medication (anticoagulants) long-term.
  • People who had a mechanical heart valve fitted either before or during their surgery.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 02.44.76.85.69

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
19 March 2024
Est. completion
19 March 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

To compare the rate of recurrence of paroxysmal or persistent atrial fibrillation with continuous 12-month postoperative cardiac surgery monitoring in patients with POAF versus traditional follow-up with ECG recording at 3, 6 and 12 months

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov